Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 7/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.49 |
| ▸ | DUT | P33316 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | IDE | P14735 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.42 |
| ▸ | HLCS | P50747 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38652488 | 0.87 | F2 (0.64) | F2TDP1 | |
| Biotin SCHEMBL523980 | 0.85 | TDP1 (0.51) | F2TDP1DUTMEN1ABL1 | |
| Biotin SCHEMBL381578 | 0.85 | DUT (0.52) | F2TDP1DUT | |
| SCHEMBL6223080 | 0.81 | DUT (0.55) | DUT | |
| SCHEMBL523981 | 0.81 | F2 (0.47) | F2DUT | |
| SCHEMBL28085620 | 0.79 | TDP1 (0.60) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL23982127 | 0.79 | HLCS (0.61) | F2HLCS | |
| SCHEMBL6041222 | 0.78 | DUT (0.58) | DUTLMNA | |
| SCHEMBL18670762 | 0.77 | DUT (0.57) | DUT | |
| Biotin SCHEMBL4304275 | 0.76 | TDP1 (0.44) | F2TDP1DUTMEN1ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102283836-B | Application of sorafenib in treatment of early brain injury (EBI) after subarachnoid hemorrhage (SAH) | FIRST AFFILIATED HOSPITAL SOOCHOW UNIV | 2013-01-09 | — | — | CN | disclosed |
| CN-102283836-A | Application of sorafenib in treatment of early brain injury (EBI) after subarachnoid hemorrhage (SAH) | — | 2011-12-21 | — | — | CN | disclosed |
| US-20100240674-A1 | USE OF COMPOUNDS DERIVED FROM BENZAMIDINE METHANESULPHONATE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, FOR EXAMPLE IMATINIB MESYLATE, FOR THE PREPARATION O F A DRUG FOR THE TREATMENT OF NEURODEGENERATIVE NIEMANN-PICK C DISEASE (NPC) | PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE (CL) | 2010-09-23 | — | — | US | disclosed |